CA2871545A1 - Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists - Google Patents

Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists Download PDF

Info

Publication number
CA2871545A1
CA2871545A1 CA 2871545 CA2871545A CA2871545A1 CA 2871545 A1 CA2871545 A1 CA 2871545A1 CA 2871545 CA2871545 CA 2871545 CA 2871545 A CA2871545 A CA 2871545A CA 2871545 A1 CA2871545 A1 CA 2871545A1
Authority
CA
Canada
Prior art keywords
alkyl
dioxine
benzo
carboxylic acid
series consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2871545
Other languages
English (en)
French (fr)
Inventor
Marc Nazare
Detlef Kozian
Martin Bossart
Werngard Czechtizky
Andreas Evers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA2871545A1 publication Critical patent/CA2871545A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA 2871545 2012-05-18 2013-05-16 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists Abandoned CA2871545A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305553.5 2012-05-18
EP12305553 2012-05-18
PCT/EP2013/060172 WO2013171318A1 (en) 2012-05-18 2013-05-16 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists

Publications (1)

Publication Number Publication Date
CA2871545A1 true CA2871545A1 (en) 2013-11-21

Family

ID=48468297

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2871545 Abandoned CA2871545A1 (en) 2012-05-18 2013-05-16 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists

Country Status (16)

Country Link
US (1) US9221784B2 (enExample)
EP (1) EP2850070B1 (enExample)
JP (1) JP6238970B2 (enExample)
KR (1) KR20150016304A (enExample)
CN (1) CN104302633B (enExample)
AU (1) AU2013261719B2 (enExample)
BR (1) BR112014028189A2 (enExample)
CA (1) CA2871545A1 (enExample)
ES (1) ES2649438T3 (enExample)
IL (1) IL235219A (enExample)
MX (1) MX354521B (enExample)
PL (1) PL2850070T3 (enExample)
RU (1) RU2647727C2 (enExample)
SG (1) SG11201407216YA (enExample)
SI (1) SI2850070T1 (enExample)
WO (1) WO2013171318A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200215085A1 (en) * 2017-07-19 2020-07-09 Uti Limited Partnership Method to Abate Acute Airway Hypersensitivity and Asthma Attacks
KR20250140741A (ko) 2024-03-19 2025-09-26 경북대학교 산학협력단 알룰로스를 포함하는 혈전 예방 또는 개선용 조성물 및 이의 이용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4056540A (en) 1974-01-01 1977-11-01 Bristol-Myers Company 4-Phenyl-1,3-benzodioxans
US4056450A (en) 1975-06-30 1977-11-01 M & T Chemicals Inc. Continuous detinning system
FR2424914A2 (fr) * 1978-05-03 1979-11-30 Roussel Uclaf Nouveaux derives de (1-3) benzodioxine, un procede pour leur preparation et leur application comme medicaments
SE445553B (sv) * 1978-05-03 1986-06-30 Roussel Uclaf /4h/-1,3-bensodioxan-2-karboxylsyraderivat
GB8310407D0 (en) * 1982-05-12 1983-05-25 Ici Plc 1 3 - dioxan -5- ylalkenoic acids
FR2704857B1 (fr) * 1993-05-07 1995-06-23 Adir Nouvelles benzodioxines substituées, leur procédé de préparation et les compositions pharmaceutiques les contenant.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
CN101124226A (zh) * 2004-05-07 2008-02-13 记忆药物公司 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮以及它们的制备和用途
WO2010042600A2 (en) * 2008-10-08 2010-04-15 The Uab Research Foundation Photo-activatable therapeutic agents and methods of using

Also Published As

Publication number Publication date
IL235219A (en) 2017-03-30
EP2850070B1 (en) 2017-08-23
KR20150016304A (ko) 2015-02-11
RU2014151240A (ru) 2016-07-10
BR112014028189A2 (pt) 2017-06-27
MX354521B (es) 2018-03-08
AU2013261719A1 (en) 2014-12-18
ES2649438T3 (es) 2018-01-12
WO2013171318A1 (en) 2013-11-21
MX2014014012A (es) 2015-02-12
CN104302633B (zh) 2016-09-07
SI2850070T1 (en) 2018-01-31
SG11201407216YA (en) 2014-12-30
PL2850070T3 (pl) 2018-01-31
JP2015517515A (ja) 2015-06-22
RU2647727C2 (ru) 2018-03-19
AU2013261719B2 (en) 2017-07-27
US20150111889A1 (en) 2015-04-23
CN104302633A (zh) 2015-01-21
EP2850070A1 (en) 2015-03-25
JP6238970B2 (ja) 2017-11-29
US9221784B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
US6258817B1 (en) Substituted pyrazin-2-yl-sulphonamide (-3-pyridyl) compounds and uses thereof
US5668137A (en) N-heterocyclic sulfonamides having endothelin receptor activity
CZ297544B6 (cs) Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy
AU2021376280A1 (en) 2-pyridones as thyroid hormone receptor modulators
US9346762B2 (en) Pyrazole derivatives and their use as LPAR5 antagonists
US9315492B2 (en) Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof
AU2013261719B2 (en) Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists
EP2850062B1 (en) Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
JP2021524469A (ja) Ｎｒｆ２アクチベーターとしてのインダン
CA2989982A1 (en) Imidazodiazepine compound
EP2860176A1 (en) Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof
RU2360910C2 (ru) Производные триазола как ингибиторы 11-бета-гидроксистероиддегидрогеназы-1
TW202235408A (zh) 化合物
HK1005801B (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
JP2014517035A (ja) Ｍｇｌｕ２受容体アゴニストとしてのビシクロ（３．１．０）ヘキサン−２，６−ジカルボン酸誘導体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180509

FZDE Dead

Effective date: 20201026